Thompson Siegel & Walmsley’s TriSalus Life Sciences TLSI Stock Holding History
Bought
Maintained
Sold
Other funds holding TLSI
Thompson Siegel & Walmsley's TLSI Position: Q3 2026 in Review
Thompson Siegel & Walmsley reduced its TriSalus Life Sciences (TLSI) stake by 1.3% in Q3 2026, selling an estimated $33.2K and leaving 529,534 shares worth $2.28M. The position accounts for 0.04% of the portfolio, ranked #288.
Thompson Siegel & Walmsley first reported a position in TLSI in Q1 2026 and has held it in 3 quarters since. The position peaked at $2.44M in Q2 2026. 82 funds tracked by Wall St. Rank hold TLSI as of Q3 2026.
- Thompson Siegel & Walmsley held 529,534 shares of TriSalus Life Sciences worth $2.28M as of Q3 2026.
- Thompson Siegel & Walmsley sold 7,000 TriSalus Life Sciences shares in Q3 2026, an estimated $33.2K.
- TriSalus Life Sciences made up 0.04% of Thompson Siegel & Walmsley's portfolio in Q3 2026, its #288 holding.
- Thompson Siegel & Walmsley first reported a position in TriSalus Life Sciences in Q1 2026 and has held it in 3 quarters since.
- Thompson Siegel & Walmsley's TriSalus Life Sciences position peaked at $2.44M in Q2 2026.
- 82 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q3 2026.
Based on Thompson Siegel & Walmsley's 13F filing for Q3 2026, filed 5 Nov 2026.